BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Rare metabolic and lysosomal diseases clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for lysosomal storage diseases: 111 (51 sponsors; 15 newly posted in the last 180 days, 5 stopped in the last 180 days; 7 new-entrant sponsors). Momentum score 21.6, rank 23 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 0, Phase 1 5, Phase 2 35, Phase 3 34, Phase 4 4, N/A 33.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Sanofi SNY7P3 5, NA 210
Azafaros B.V.6P3 4, P2 220
JCR Pharmaceuticals Co., Ltd.7P2 3, P3 3, NA 111
Amicus Therapeutics6NA 3, P3 302
Chiesi Farmaceutici S.p.A.5P3 2, NA 300
Denali Therapeutics Inc. DNLI5P3 2, P2 300
REGENXBIO Inc. RGNX4P3 2, NA 200
Ultragenyx Pharmaceutical Inc RARE4P3 2, NA 210
Orchard Therapeutics3P2 1, P3 200
QED Therapeutics, a BridgeBio company5NA 1, P2 3, P3 101
Takeda TAK3P3 1, NA 200
Spur Therapeutics2P2 1, P3 100
AO GENERIUM1P3 100
CANbridge Life Sciences Ltd. new entrant1P3 110
Idorsia Pharmaceuticals Ltd. new entrant1P3 110
IntraBio Inc1P3 100
Regeneron Pharmaceuticals REGN1P3 100
Spruce Biosciences SPRB1P3 100
Genzyme, a Sanofi Company7NA 4, P4 2, P2 100
Prevail Therapeutics3P2 301
Shionogi3P1 1, P2 220
4D Molecular Therapeutics FDMT2P2 200
Astellas Gene Therapies2NA 1, P2 100
GC Biopharma Corp2P1 200
Phoenix Nest2NA 210

New-entrant sponsors: CANbridge Life Sciences Ltd., Idorsia Pharmaceuticals Ltd..

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P1/P2GeneCradle IncNCT06391736 Evaluation of the Safety and Efficacy of Late-onset Pompe Disease Gene Therapy DrugPompe Disease (Late-onset)recruiting33
2026-12-31 est.P2JCR Pharmaceuticals Co., Ltd.NCT03708965 An Extension Study of JR-141-BR21 in Patients With Mucopolysaccharidosis IIMucopolysaccharidosis IIactive not recruiting19
2026-12-31 est.P3Amicus TherapeuticsNCT04020055 A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal DiseaseFabry Diseaseactive not recruiting14
2027-02 est.P1/P2Prevail TherapeuticsNCT04411654 Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)Gaucher Disease, Type 2active not recruiting7

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10-30 est.P2Genzyme, a Sanofi CompanyNCT02843035 Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy ExtensionGaucher Disease Type 1; Gaucher Disease Type 3active not recruiting12
2026-08-31P3Idorsia Pharmaceuticals Ltd.NCT03737214 A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry DiseaseFabry Diseasecompleted107
2026-08-10 est.P1/P2ModernaTX, Inc.NCT06147856 A Dose-finding Study to Evaluate mRNA-3210 in Participants With PhenylketonuriaPhenylketonuriawithdrawn
2026-07-21P3PTC Therapeutics PTCNCT05166161 A Long-Term Safety Study of PTC923 in Participants With PhenylketonuriaPhenylketonuriacompleted247
2026-06 est.P1/P24D Molecular Therapeutics FDMTNCT05629559 4D-310 in Adults With Fabry Disease and Cardiac InvolvementFabry Diseaserecruiting18

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "lysosomal storage diseases"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.